Rover Metals Announces the Appointment of McGinley and Associates for Its NEPA Permitting Process at the LGL Project, NV, USA
VANCOUVER, BC / ACN Newswire / September 26, 2023 / Rover Metals Corp. (TSXV:ROVR)(OTCQB:ROVMF)(FSE:4XO) (“Rover”…
News
KBRA Releases Report for Allegheny County Airport Authority (Pittsburgh International Airport) Airport Revenue Bonds
NEW YORK–(BUSINESS WIRE)–#KBRA–On September 21, 2023, KBRA assigned an A+ rating with a Stable Outlook…
New Missouri Siddens Benning Hands-Free Law Has Prevented 80 Crashes
Research from Cambridge Mobile Telematics shows a 2.86% reduction in phone motion distraction in Missouri…
Wolters Kluwer appoints Rafael Sidi as Health Research segment leader
WALTHAM, Mass.–(BUSINESS WIRE)–Wolters Kluwer Health has appointed Rafael Sidi as Senior Vice President & General…
Acra Lending Partners with Tavant, Deploys Touchless Lending® Collateral Analysis
Joint implementation with Acra solidifies Tavant’s presence within the Non-QM space and will progress with…
Broadcom Partners with Google Cloud to Strengthen Gen AI-Powered Cybersecurity
Symantec combines global threat intelligence with Google Cloud’s gen AI expertise to simplify threat analysis…
Banyan Security Introduces Groundbreaking Zero Trust Clientless Solution for Secure Remote Access in the Healthcare Industry
Focused on the Unique Security Needs of Healthcare: It Ensures Seamless and Protected Access for…
Broadcom Partners with Google Cloud to Strengthen Gen AI-Powered Cybersecurity
Symantec combines global threat intelligence with Google Cloud’s gen AI expertise to simplify threat analysis…
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children…
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children…
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational,…
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational,…
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is…
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is…
Synfini, Inc. Spins Out of SRI International to Bring Novel Molecular Discovery Platform to Market
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive…
Synfini, Inc. Spins Out of SRI International to Bring Novel Molecular Discovery Platform to Market
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive…
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first…
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first…
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development…
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development…